Skip to content

Study · Randomized controlled trial · 2009

2 results

[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)].

Neznamov GG, Siuniakov SA, Teleshova SE, Chumakov DV, Reutova MA, Siuniakov TS, Mametova LE, Dorofeeva OA, Grishin SA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2009

PMID19491814 (opens in a new tab)PepBankPUB-19491814
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with neurasthenia, ladasten was superior to placebo in the rate and degree of reduction of main asthenic symptoms.

    In plain wordsIn patients with neurasthenia, ladasten was better than placebo in how fast and how much main asthenic symptoms fell.

    Peptide
    Bromantane
    Outcome
    DecreaseRate and degree of reduction of main asthenic symptoms
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Fatigue · Whole body
    Studied dose
    Dose not stated · 28 daysAs given in this study (human).

    Source sentences

    Summary
    It has been found that ladasten is superior in the rate and degree of reduction of main symptoms of asthenic syndrome compared to placebo.
    2 context sentences
    Summary · context
    An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia.
    Summary · context
    The design of the study included a wash-out period, a monotherapy with ladasten and placebo during 28 days and a final 1-week period of receiving placebo.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with neurasthenia, no withdrawal syndrome occurred after ladasten withdrawal.

    In plain wordsIn patients with neurasthenia, the study found no withdrawal syndrome after ladasten treatment ended.

    Peptide
    Bromantane
    Outcome
    Not applicableWithdrawal syndrome
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 28 daysAs given in this study (human).

    Source sentences

    Summary
    The absence of "withdrawal syndrome" after the drug withdrawal reveals the lack of addictive potential in this drug.
    2 context sentences
    Summary · context
    An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia.
    Summary · context
    The design of the study included a wash-out period, a monotherapy with ladasten and placebo during 28 days and a final 1-week period of receiving placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.